Correction To: White Matter Changes in Primary Central Nervous System Lymphoma Patients Treated With High-Dose Methotrexate With or Without Rituximab

Journal of Neuro-Oncology - Netherlands
doi 10.1007/s11060-019-03346-1
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

High-Dose Methotrexate With or Without Rituximab in Newly Diagnosed Primary CNS Lymphoma

Neurology
Neurology
2014English

Frequency, Risk Factors, and Outcomes of Central Nervous System Relapse in Lymphoma Patients Treated With Dose-Adjusted EPOCH Plus Rituximab

American Journal of Hematology
Hematology
2017English

Contrast-Enhanced MRI Texture Parameters as Potential Prognostic Factors for Primary Central Nervous System Lymphoma Patients Receiving High-Dose Methotrexate-Based Chemotherapy

Contrast Media and Molecular Imaging
MedicineNuclear MedicineRadiologyImaging
2019English

Primary Central Nervous System Lymphoma: Coming or Going?

Blood
BiochemistryImmunologyCell BiologyHematology
2009English

Primary Central Nervous System Lymphoma

Therapeutic Advances in Neurological Disorders
NeurologyPharmacology
2018English

Primary Central Nervous System Lymphoma

Contemporary Neurosurgery
2010English

Effect of Intravitreous Rituximab Injections in Patients With Recurrent Ocular Lesions Associated With Central Nervous System Lymphoma

Archives of Ophthalmology
2008English

Primary Central Nervous System Lymphoma With Lateral Ventricle Involvement

The Open Medical Imaging Journal
2012English

Primary Central Nervous System Lymphoma

Journal of Neurosurgery
SurgeryNeurology
1985English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy